Mayne Pharma Group Limited (ASX:MYX) has advised that Dr Brett Wells has requested the withdrawal of resolution 4 — his director election resolution — from the notice of meeting for the company's Annual General Meeting scheduled for Friday, 20 November 2026, following the company's execution of a Scheme Implementation Deed with Gedeon Richter Plc.

Key Points

  • Dr Brett Wells requested the withdrawal of resolution 4, his director election resolution, from the AGM notice of meeting.
  • The withdrawal follows Mayne Pharma's execution of a Scheme Implementation Deed (SID) with Gedeon Richter Plc, announced on the same day.
  • Resolution 4 will not be put to shareholders at the 20 November 2026 AGM.
  • All other items of business in the notice of meeting will proceed as originally notified.

Withdrawal of Dr Brett Wells Election Resolution

According to the filing, dated 17 November 2026 from Adelaide, Australia, Dr Brett Wells requested that Mayne Pharma Group Limited withdraw resolution 4 from the AGM notice of meeting. Resolution 4 concerned Dr Wells' election as a director of the company. The company confirmed that resolution 4 is withdrawn and will not be put to shareholders at the AGM to be held on Friday, 20 November 2026. The filing states the withdrawal was made as a direct result of the company's announcement regarding the execution of a Scheme Implementation Deed with Gedeon Richter Plc.

Scheme Implementation Deed with Gedeon Richter Plc

The filing discloses that Mayne Pharma announced the execution of a Scheme Implementation Deed with Gedeon Richter Plc on 17 November 2026, the same date as the AGM update. The company identified this transaction as the reason Dr Wells requested the withdrawal of his director election resolution. No further details of the Scheme Implementation Deed terms or its financial particulars are disclosed within this filing. The company did not provide additional context regarding the nature or structure of the arrangement with Gedeon Richter Plc beyond identifying it as a SID.

AGM Proceedings on 20 November 2026

Mayne Pharma confirmed that all other items of business set out in the notice of meeting for the AGM will proceed as notified. The Annual General Meeting remains scheduled for Friday, 20 November 2026. The filing was authorised for release by the Board Chair. Mayne Pharma is described in the filing as an ASX-listed specialty pharmaceutical company focused on dermatology and women's health in the United States, as well as contract development and manufacturing services, with a 40-year track record in developing oral drug delivery systems.